› $150,000,000 verdict in personal injury case
Doctors said Gentrie Hansen’s uncontrollable bouts of nausea and vomiting were caused by bulimia, the eating disorder in which victims force themselves to throw up food they eat to keep from gaining weight. But 14-year-old Gentrie knew better. “The worst part of my whole sickness was people telling you ‘you have an eating disorder’ and you know something else is wrong and you really want your food,” she told the Today show.
Diabetics who suffer from nausea, vomiting, bloating, or abdominal discomfort after eating may be eligible to participate in a study for an investigational medication to reduce the symptoms associated with delayed stomach emptying, also known as gastroparesis, a condition many diabetics experience.
Very low doses of inhaled carbon monoxide has been shown to reverse a serious digestive condition in diabetic mice, a finding that could give hope to millions of sufferers of diabetic gastroparesis. The findings are based on a study conducted by researchers with the Mayo Clinic and presented at last year’s Digestive Disease Week gathering.
Thirty-two-year-old Shimmi Munshi would get sick up to 50 times a day over a four-year period, but doctors were at a loss as to why. She was put on feeding tubes and medication, but the treatments did little to help her. She became sicker and weaker. It wasn’t until the young woman scoured the Internet that she some answers. She immediately diagnosed herself with gastroparesis, or paralysis of the stomach. And found a treatment that would help her live a normal life.
Be your own advocate. That is what the Gastroparesis, etc… blogger suggests for people, like her, who suffer from gastroparesis, a condition in which the stomach takes too long to empty its contents. The blogger can be found at gpadvocate.wordpress.com.
Tranzyme Pharma’s new drug to treat diabetic gastroparesis has been granted a fast-track designation by the Food and Drug Administration (FDA), allowing it faster access to FDA personnel as it moves through the approval process. The new medication, called TZP-102, has just moved into phase II trials in humans. If the trials run smoothly, the drug should enter phase III trials next year with approval by 2013 at the earliest. The fast-track designation is reserved for drugs that treat serious and unmet medical needs.
